Find Out What

Can Mean for Your Patients1-3

Mozobil + granulocyte-colony stimulating factor (G-CSF) has been shown to improve mobilization compared to G-CSF alone in patients with non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM).

Get the Details

About Mozobil

Mozobil is indicated in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with NHL or MM.1

Mozobil is a first in class CXCR4 receptor antagonist.1

more about mozobil

Dosing and Administration

Begin treatment with Mozobil after the patient has received G-CSF once daily for 4 days. Administer Mozobil approximately 11 hours before initiation of each apheresis while continuing daily G-CSF administration. Mozobil administration can be up to 4 consecutive days.1

More about dosing and administration

Sanofi Is Committed to Helping Patients

Sanofi Patient Connection is a program designed to assist patients through 3 main types of patient support:

  • Patient Assistance Connection: Providing patients who meet eligibility criteria with their prescribed medications at no cost
  • Reimbursement Connection: Supporting patients and providers in determining insurance coverage, including benefit verification, prior authorization, and appeals assistance
  • Resource Connection: Helping identify additional appropriate resources and support for program patients

LEARN MORE ABOUT SANOFI PATIENT CONNECTION

Abbreviations: CXCR4, C-X-C motif chemokine receptor 4; G-CSF, granulocyte-colony stimulating factor; MM, multiple myeloma; NHL, non-Hodgkin's lymphoma.

REFERENCES:

  1. Mozobil [prescribing information]. Cambridge, MA: Genzyme Corporation; 2020.
  2. DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27(28):4767-4773.
  3. DiPersio JF, Stadtmauer EA, Nademanee A, et al; for the 3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720-5726.